Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (GKOS) is a leader in ophthalmic medical technology, pioneering micro-invasive glaucoma surgery (MIGS) and transformative eye care solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access timely press releases covering product approvals, financial results, and research developments directly impacting glaucoma treatment paradigms. Our curated collection includes updates on therapeutic innovations, partnership announcements, and progress in addressing various stages of ocular disease.
Bookmark this page for streamlined access to Glaukos' latest achievements in medical device engineering and surgical techniques. Regularly updated content ensures you stay informed about developments influencing both patient care and the evolving ophthalmic technology landscape.
Glaukos (NYSE: GKOS) reported strong financial results for Q2 2024, with record net sales of $95.7 million, up 19% year-over-year. The company's Glaucoma segment saw a 23% increase in net sales to $75.9 million, while Corneal Health net sales grew 7% to $19.8 million. Gross margin improved to 76%, with non-GAAP gross margin at 82%. Despite the revenue growth, Glaukos reported a net loss of $53.9 million, or ($1.06) per diluted share. The company raised its 2024 net sales guidance to $370-$376 million, up from the previous $357-$365 million range. Glaukos ended the quarter with approximately $266.4 million in cash and investments.
Glaukos (NYSE: GKOS), specializing in ophthalmic pharmaceuticals and medical technology, will release its second quarter 2024 financial results after market close on Wednesday, July 31, 2024. The announcement will be discussed by company management during a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).
Access to the live webcast will be available on the company's investor relations website. Interested parties can join the conference call by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) with the Conference ID 7935742. A replay will be available on Glaukos' website after the call.
Glaukos (NYSE: GKOS) has entered into privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due 2027.
The company plans to repurchase $230 million in principal amount of these notes. The consideration will comprise shares of Glaukos' common stock and cash for fractional shares and accrued interest.
The exchanges are expected to close around June 25, 2024, and the shares issued will not be registered under the Securities Act of 1933.
This action is not an offer to sell or a solicitation to buy these securities in any jurisdiction where such actions would be illegal.
Glaukos (NYSE: GKOS) has announced its participation in two upcoming investor conferences: the William Blair 44th Annual Growth Stock Conference on June 5, 2024, at 1:40 p.m. ET in Chicago, and the Truist MedTech Conference on June 18, 2024, at 12:45 p.m. ET in Boston. Glaukos specializes in therapies for glaucoma, corneal disorders, and retinal diseases. Live and archived webcasts of these events will be available on the Glaukos website.
Glaukos (NYSE: GKOS) reported strong financial results for the first quarter of 2024, with record net sales of $85.6 million, marking a 16% increase year-over-year. The company raised its 2024 net sales guidance to $357 to $365 million. Glaukos continues to focus on developing innovative technologies to enhance patient care in ophthalmology.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
